How to Choose a Saudi Distributor (and the Five Contract Clauses That Protect You)

Ask a manufacturer who has been in the Gulf for ten years what they would do differently, and the answer is almost never about registration or pricing. It is about the first distributor. A good one turns a registration into a business; a wrong one costs two to three years, and unwinding the relationship can cost more than the sales it produced. This guide sets out how the Saudi distribution landscape actually looks, how to evaluate candidates, and the five clauses that decide whether you stay in control of your own product.

1. Distributor and Authorized Representative are two different roles

Under SFDA rules, a foreign manufacturer needs a Saudi-resident Authorized Representative (AR) to hold its Medical Device Marketing Authorization (MDMA). Commercially, it needs a distributor that imports, stocks, sells, delivers, and services the product. Nothing requires these to be the same company.

Many distributors ask to be the AR as well. Sometimes that is efficient; often it is a way to make a future distributor change feel impossible. The MDMA is issued for the manufacturer's product and the AR holds it on the manufacturer's behalf, but the practical friction of transferring files, import authorizations, and hospital records in the middle of a dispute is real. Decide deliberately: an independent AR keeps regulatory continuity separate from commercial performance, at a modest additional cost.

2. The three kinds of Saudi distributor

The large multi-line houses. Long-established groups with dozens of agencies, national coverage, strong tender departments, and deep institutional relationships. They can win NUPCO frameworks and place a product in the major hospitals quickly. The risk is attention: your product may be one of three hundred, and if it does not move in year one, it moves to the back of the catalogue.

The specialist mid-size distributors. Focused on one or two therapeutic areas (surgery, wound care, aesthetics, diagnostics, orthopaedics), with clinical specialists on staff and credibility in their niche. Often the best fit for a differentiated product that needs clinical selling rather than shelf presence. The limits are geographic coverage and balance sheet for large tenders.

The ambitious small companies. Founder-led, hungry, responsive, and frequently built around one or two strong hospital relationships. They can outperform larger houses in a single institution or region, and they will give your product real focus. The risks are financial capacity for bonds and stock, thin management, and dependence on one or two people.

There is no universally right choice. The right choice depends on your product's channel: a commodity consumable sold through NUPCO frameworks needs a different partner from a premium device sold surgeon by surgeon.

3. The evaluation scorecard

Evaluate every candidate against the same criteria, and score them before the commercial conversation starts.

A candidate that scores well on paper but cannot introduce you to a single hospital decision-maker during due diligence is telling you something.

4. The five clauses that protect you

Every distribution agreement for Saudi Arabia should be reviewed by qualified Saudi counsel before signature. The points below are the commercial essentials that we see decide, years later, whether a manufacturer still controls its own product.

1. Exclusivity tied to performance. If you grant exclusivity (and most Saudi distributors will ask for it), tie it to annual minimum purchase or sales targets, agreed in writing, reviewed yearly. Missing the target should convert exclusivity to non-exclusivity automatically, without the need to terminate. This single clause resolves most distributor problems without a dispute.

2. Registration ownership and transfer. State explicitly that all SFDA registrations, technical files, and related records are the manufacturer's property; that the distributor (or AR) will cooperate fully with any transfer on request; and that this obligation survives termination. Include the same language for any hospital vendor registrations and tender qualifications obtained in your name.

3. Term, renewal, and notice. Prefer a defined initial term (two to three years is common) with renewal by mutual agreement, and define notice periods clearly and realistically for both sides. Your counsel should confirm how term and notice interact with local rules on agency and distribution agreements.

4. Termination for cause and exit mechanics. Define the events that allow termination for cause (missed targets after a cure period, breach of compliance or anti-bribery obligations, insolvency, change of control, failure to maintain licences). Address what happens to stock, open tenders, customer records, and warranty obligations on exit, so that a change of partner does not interrupt supply to hospitals.

5. Pricing, territory, and brand protection. Fix how prices to the market are set and changed; prohibit sales outside the territory and to unauthorised sub-distributors without consent; require compliance with your labelling, storage, and promotional standards; and reserve your right to sell directly to defined accounts (for example, national tenders or a specific institution) if the distributor cannot serve them.

Two further points are less about clauses and more about structure. Keep a copy of every document submitted in your name. And never let the first agreement run longer than the first year of evidence justifies; extend on performance, not on promise.

5. Red flags in the first meeting

• The candidate wants exclusivity for the whole GCC, immediately, before selling a single unit in Saudi Arabia.
• They insist on being the Authorized Representative and resist any discussion of why.
• They cannot name the clinicians or procurement staff who would champion your product.
• Your competitor's product is already in their catalogue and they see no conflict.
• They promise a NUPCO framework award as though it were within their gift.
• Financial statements are unavailable or "with the auditor".
• The person who impressed you in the meeting will not be the person managing your line.

Frequently asked questions

Can I appoint more than one distributor in Saudi Arabia?

Yes, by channel, region, or product line, provided the agreements say so clearly. Non-exclusive or segmented arrangements are common for large portfolios.

Should the distributor pay for registration?

It is negotiable. Many manufacturers fund registration to keep clear ownership of the file; others let the distributor fund it in exchange for exclusivity. Whoever pays, ownership and transfer should be defined in writing.

How long should a first agreement run?

Long enough for the distributor to justify investment (typically two to three years), short enough that under-performance can be corrected. Performance-linked exclusivity matters more than the length itself.

What if the relationship goes wrong?

Most problems are resolved commercially if the agreement has clear targets, a cure period, and a defined exit. Well-drafted agreements rarely need more than that.

Related reading: SFDA Registration (MDMA) · Why Foreign Manufacturers Get Disqualified from NUPCO Tenders

This article is general commercial guidance as of the date above and does not constitute legal advice. Obtain advice from qualified Saudi counsel before signing any distribution or agency agreement.